title: Yttrium 90-labeled antiferritin followed by high-dose chemotherapy and autologous bone marrow transplantation for poor-prognosis Hodgkin's disease.
abstract: OBJECTIVE
  This study was undertaken to examine the feasibility of combining radiolabeled antibody therapy with high-dose chemotherapy followed by autologous bone marrow transplantation in patients with poor-prognosis Hodgkin's disease.
  
  
  METHODS
  Patients were entered onto this protocol if they had chemotherapy-resistant disease, bulky disease, or extensive prior therapy. Patients received yttrium-labeled antiferritin on day -13, -12, or -11, followed by high-dose cyclophosphamide, carmustine, and etoposide (CBV) on days -6 to -3, and then bone marrow infusion on day 0.
  
  
  RESULTS
  Twelve patients received both radiolabeled antibody and high-dose chemotherapy followed by autologous transplantation. Two additional patients started the study, but were unable to complete all therapy. Four of 12 patients experienced early transplant-related mortality. Four patients are alive more than 2 years following transplantation and three are free from disease progression at 24+, 25+, and 28+ months following transplantation. The progression-free survival rate at 1 year is estimated to be 21%. Considering the poor prognostic characteristics of these patients, toxicity on this protocol was not necessarily greater than that observed with high-dose chemotherapy alone.
  
  
  CONCLUSIONS
  This report demonstrates the feasibility of combining radiolabeled antibody therapy with high-dose chemotherapy and autologous bone marrow transplantation.
authors: Department of Internal Medicine, University of Nebraska Medical Center, Omaha 68198-3330.
authors: P J
authors: PJ
authors: Bierman
authors: J M
authors: JM
authors: Vose
authors: P K
authors: PK
authors: Leichner
authors: S M
authors: SM
authors: Quadri
authors: J O
authors: JO
authors: Armitage
authors: J L
authors: JL
authors: Klein
authors: R A
authors: RA
authors: Abrams
authors: K A
authors: KA
authors: Dicke
authors: H M
authors: HM
authors: Vriesendorp
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D002330:Carmustine / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D005293:Ferritins / Q000276:immunology; D006689:Hodgkin Disease / Q000401:mortality / Q000628:therapy*; D006801:Humans; D008297:Male; D009363:Neoplasm Proteins / Q000276:immunology; D011379:Prognosis; D016499:Radioimmunotherapy; D015996:Survival Rate; D015021:Yttrium Radioisotopes
chemical_list: D009363:Neoplasm Proteins; D015021:Yttrium Radioisotopes; D005047:Etoposide; D003520:Cyclophosphamide; D005293:Ferritins; D002330:Carmustine